TABLE 3.
Comparison of mean change from baseline in outcomes between three groups.
| 4 ml group (n = 21) | 2 ml group (n = 21) | 1 ml group (n = 21) | p-Value a | |
|---|---|---|---|---|
| Primary outcome ΔVAS | ||||
| 1 week | −2.38 (1.81) | −1.42 (1.61) | −1.60 (1.63) | 0.151 |
| 4 weeks | −3.52 (2.22) | −1.93 (2.52) | −1.31 (1.41) | 0.003** |
| 12 weeks | −3.86 (1.69) | −2.43 (2.72) | −1.69 (1.54) | 0.004** |
| 24 weeks | −3.17 (2.18) | −3.14 (2.37) | −1.90 (2.12) | 0.119 |
| Secondary outcome | ||||
| ΔBCTQ (SD) | ||||
| 1 week | −15.43 (8.83) | −7.76 (11.20) | −8.24 (7.09) | 0.014* |
| 4 weeks | −20.38 (9.55) | −11.29 (12.95) | −8.48 (6.67) | 0.001** |
| 12 weeks | −20.52 (9.81) | −12.62 (14.19) | −9.86 (9.72) | 0.010* |
| 24 weeks | −15.52 (12.07) | −14.76 (11.93) | −10.62 (10.55) | 0.340 |
| ΔBCTQ-S (SD) | ||||
| 1 week | −8.57 (4.88) | −4.95 (7.47) | −5.67 (4.88) | 0.163 |
| 4 weeks | −12.00 (6.90) | −7.52 (8.05) | −5.91 (5.14) | 0.015* |
| 12 weeks | −12.10 (6.16) | −8.62 (8.94) | −7.76 (7.48) | 0.157 |
| 24 weeks | −9.67 (8.22) | −9.91 (7.23) | −7.95 (7.76) | 0.674 |
| ΔBCTQ-F (SD) | ||||
| 1 week | −6.86 (4.14) | −2.81 (4.84) | −2.57 (2.46) | 0.001** |
| 4 weeks | −8.38 (4.54) | −3.76 (5.64) | −2.57 (2.48) | 0.0002** |
| 12 weeks | −8.43 (5.65) | −4.00 (6.24) | −2.10 (3.32) | 0.001** |
| 24 weeks | −5.86 (5.10) | −4.86 (5.69) | −2.67 (3.76) | 0.108 |
| ΔQuickDASH (SD) | ||||
| 1 week | −9.33 (5.89) | −4.29 (6.27) | −4.14 (5.49) | 0.008** |
| 4 weeks | −11.62 (6.70) | −6.48 (7.79) | −4.67 (5.67) | 0.004** |
| 12 weeks | −11.19 (6.87) | −6.91 (8.73) | −5.19 (5.75) | 0.027* |
| 24 weeks | −8.62 (6.90) | −8.57 (7.08) | −6.81 (5.64) | 0.599 |
| Electrodiagnosis (SD) | ||||
| ΔMotor DL, ms | ||||
| 1 week | 0.06 (0.54) | 0.01 (0.88) | −0.33 (0.96) | 0.294 |
| 4 weeks | 0.37 (1.09) | −0.13 (0.58) | −0.08 (0.63) | 0.124 |
| 12 weeks | 0.15 (0.87) | −0.16 (0.62) | −0.08 (0.60) | 0.375 |
| 24 weeks | 0.09 (0.95) | −0.32 (0.72) | −0.09 (0.57) | 0.263 |
| ΔSNCV finger-wrist | ||||
| 1 week | 0.45 (3.66) | 0.80 (4.63) | 0.00 (4.14) | 0.841 |
| 4 weeks | 0.55 (3.03) | 1.56 (3.43) | −0.48 (5.16) | 0.307 |
| 12 weeks | 3.11 (3.79) | 1.59 (3.15) | 0.44 (4.89) | 0.138 |
| 24 weeks | 3.52 (3.71) | 2.45 (3.79) | 0.40 (4.32) | 0.055 |
| ΔSNCV palm-wrist | ||||
| 1 week | 0.69 (3.20) | 0.03 (3.53) | 0.27 (2.95) | 0.816 |
| 4 weeks | 0.00 (3.54) | 0.02 (3.88) | 0.26 (3.89) | 0.974 |
| 12 weeks | 1.14 (2.80) | −0.54 (2.72) | 0.25 (4.77) | 0.370 |
| 24 weeks | 1.00 (4.11) | 0.499 (3.18) | 0.12 (5.28) | 0.767 |
| ΔCSA (SD), mm2 | ||||
| 1 week | −0.61 (2.68) | −0.71 (2.19) | −0.42 (1.50) | 0.917 |
| 4 weeks | −0.44 (3.31) | −0.53 (3.04) | −0.53 (3.27) | 0.996 |
| 12 weeks | −0.88 (2.45) | −1.24 (3.15) | −1.37 (3.13) | 0.879 |
| 24 weeks | −1.89 (2.28) | −2.34 (2.96) | −1.63 (2.87) | 0.720 |
D5W, 5% dextrose water; SD, standard deviation; DM, diabetes mellitus; VAS, visual analog scale; BCTQ, Boston Carpal Tunnel Syndrome Questionnaire (F, function; S, symptom severity); DL, distal latency of median nerve; SNCV, sensory nerve conduction velocity (finger-wrist, finger to wrist segment; palm-wrist, palm to wrist segment); CSA, cross-sectional area of median nerve.
*p < 0.05, **p < 0.01.
a
Between-group comparison: one-way ANOVA was used for statistical analysis.